RESUMO
OBJECTIVE: To present our experience in the diagnosis and treatment of prostate sarcoma and the clinical and prognostic features of the malignancy. METHODS: We retrospectively analyzed the clinical data on 26 cases of prostate sarcoma treated in our hospital from June 1998 to March 2018. The patients ranged in age from 15 to 64 years (ï¼»41 ± 14ï¼½ yr) and in the PSA level from 0.345 to 5.213 µg/L (ï¼»1.762 ± 1.184ï¼½ µg/L), all diagnosed with prostate sarcoma by prostatic biopsy and pathological examination after transurethral resection of the prostate (TURP). RESULTS: Postoperative pathological examination showed 11 cases of leiomyosarcoma, 6 cases of rhabdomyosarcoma, 4 cases of spindle cell sarcoma, 4 cases of fibrosarcoma and 1 case of undifferentiated sarcoma among the total number of patients. Twenty-four of the patients were followed up for 3 to 18 (mean 13) months, of whom 21 died within 12 months and the other 3 within 13ï¼18 months after diagnosis, all due to extensive metastases. CONCLUSIONS: Prostate sarcoma is a rare malignancy clinically, highly aggressive and with very poor prognosis. Surgery remains the main treatment option, but multiple disciplinary diagnosis and treatment could probably achieve a better prognosis for prostate sarcoma.